T2 Biosystems, Inc.
TTOO
$0.1315
-$0.0005-0.38%
| Weiss Ratings | TTOO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | TTOO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Weak | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | TTOO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -2.61 | |||
| Price History | TTOO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -2.59% | |||
| 30-Day Total Return | -42.83% | |||
| 60-Day Total Return | -72.32% | |||
| 90-Day Total Return | -86.42% | |||
| Year to Date Total Return | -67.13% | |||
| 1-Year Total Return | -97.16% | |||
| 2-Year Total Return | -99.77% | |||
| 3-Year Total Return | -99.99% | |||
| 5-Year Total Return | -99.99% | |||
| 52-Week High % Change | -98.06% | |||
| 52-Week Low % Change | 135.71% | |||
| Price | TTOO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $6.80 | |||
| 52-Week Low Price | $0.06 | |||
| 52-Week Low Price (Date) | Feb 14, 2025 | |||
| 52-Week High Price (Date) | Jun 24, 2024 | |||
| Valuation | TTOO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 3.70M | |||
| Enterprise Value | 20.56M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -5.94 | |||
| Earnings Per Share Growth | -97.87% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.31 | |||
| Price/Book (Q) | -0.21 | |||
| Enterprise Value/Revenue (TTM) | 2.68 | |||
| Price | $0.13 | |||
| Enterprise Value/EBITDA (TTM) | -0.50 | |||
| Enterprise Value/EBIT | -0.49 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | TTOO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 17.89M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | TTOO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 781 761 4646 | |||
| Address | 101 Hartwell Avenue Lexington, MA 02421 | |||
| Website | www.t2biosystems.com | |||
| Country | United States | |||
| Year Founded | 2006 | |||
| Profitability | TTOO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -542.59% | |||
| Profit Margin | -559.51% | |||
| Management Effectiveness | TTOO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -84.85% | |||
| Return on Equity | -- | |||
| Income Statement | TTOO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 7.68M | |||
| Total Revenue (TTM) | 7.68M | |||
| Revenue Per Share | $0.43 | |||
| Gross Profit (TTM) | -18.79M | |||
| EBITDA (TTM) | -41.40M | |||
| EBIT (TTM) | -41.66M | |||
| Net Income (TTM) | -42.95M | |||
| Net Income Avl. to Common (TTM) | -42.95M | |||
| Total Revenue Growth (Q YOY) | 34.85% | |||
| Earnings Growth (Q YOY) | 34.41% | |||
| EPS Diluted (TTM) | -5.94 | |||
| EPS Diluted Growth (Q YOY) | 83.59% | |||
| Balance Sheet | TTOO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 2.08M | |||
| Cash Per Share (Q) | $0.12 | |||
| Total Current Assets (Q) | 9.79M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -11.71M | |||
| Current Ratio (Q) | 0.400 | |||
| Book Value Per Share (Q) | -$0.62 | |||
| Total Assets (Q) | 18.08M | |||
| Total Current Liabilities (Q) | 24.44M | |||
| Total Debt (Q) | 18.94M | |||
| Total Liabilities (Q) | 29.79M | |||
| Total Common Equity (Q) | -11.71M | |||
| Cash Flow | TTOO - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -26.00K | |||
| Cash from Financing (TTM) | 14.38M | |||
| Net Change in Cash (TTM) | -22.24M | |||
| Levered Free Cash Flow (TTM) | -26.38M | |||
| Cash from Operations (TTM) | -36.59M | |||
